Healthcare AI · U.S. → EU
EU AI Act for U.S. healthcare and medical AI companies
Healthcare AI is not one single AI Act category. Classification can arise through product-linked Article 6(1)/Annex I rules or through specific Annex III use cases; intended purpose and the underlying regulatory pathway matter.
Updated and legally reviewed: 29 September 2026.
Direct answer
Do not classify an AI system as high-risk merely because it is used in healthcare.
Article 6(1) can capture AI that is itself a regulated product or safety component covered by Annex I legislation where third-party conformity assessment is required. Annex III separately lists specified uses, including decisions about eligibility for essential public healthcare services and life/health insurance risk assessment and pricing.
Medical/product route
Map the product, safety-component function, applicable Annex I legislation and conformity-assessment requirement.
Annex III route
Check the precise intended purpose rather than assuming every clinical or health-related system is listed.
U.S. market entry
EU product compliance and AI Act governance may need to be planned together.
For product-linked high-risk AI, the amended timetable points to 2 August 2028. U.S. providers should identify the product-regulatory pathway early enough to align technical documentation, testing and conformity work.
Free screening tool
Start with classification, not assumptions.
Use the relevant EU AI Act checker to identify scope, role and classification questions before building the compliance plan.